Reirradiation and teclistamab in relapsed multiple myeloma: initial experience in two heavily pretreated patients with extensive disease
Department of Oncology and Palliative Medicine, Nordland Hospital Trust, Bodø, Norway Department of Clinical Medicine, UiT – The Arctic University of Norway, Tromsø, Norway
Contemp
Oncol (Pozn) 2026; 30 (2)
-
Dores GM, Vo JB, Schonfeld SJ, Shing JZ, Taparra K, Morton LM, et al. Temporal patterns in US population-based patient survival among adults treated with chemotherapy and/or immunotherapy for multiple myeloma, 2000–2020. Br J Haematol 2025; 207: 417-425.
Terpos E, Zamagni E, Lentzsch S, Drake MT, García-Sanz R, Abildgaard N, et al. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol 2021; 22: e119-e130.
Nieder C, Pawinski A, Haukland E, Dokmo R, Phillipi I, Dalhaug A. Estimating need for palliative external beam radiotherapy in adult cancer patients. Int J Radiat Oncol Biol Phys 2010; 76: 207-211.
Kaufmann J, Täubl AU, Nikolaidou E, Rühle A, Hopprich A, Wollschläger D, et al. Excellent long-term pain response and local control following postoperative radiotherapy in patients with multiple myeloma. Strahlenther Onkol 2024; 200: 633-641.
Zhang SC, Ballas LK. Radiation for multiple myeloma in the era of novel agents: Indications, safety, and dose selection. Semin Radiat Oncol 2025; 35: 87-98.
Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022; 387: 495-505.
Andratschke N, Willmann J, Appelt AL, Alyamani N, Balermpas P, Baumert BG, et al. European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making. Lancet Oncol 2022; 23: e469-e478.
Available from: https://dctd.cancer.gov/research/ctep-trials/for-sites/adverse-events.
Lonial S, Dimopoulos MA, Berdeja JG, Richardson PG, Quach H, Rodríguez-Otero P, et al. EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol 2025; 21: 1761-1769.
Li Z, Qiu Y, Personett D, Huang P, Edenfield B, Katz J, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One 2013; 8: e71754.
Tringale KR, Imber BS, Cederquist GY, Yahalom J, Moore ZR, Hop- pe RT, et al. Urgent and emergent radiotherapy for hematologic malignancies of the central nervous system: a review of the literature and practical approach. Front Oncol 2025; 15: 1511261.
Khan MK, Nasti TH, Qian JY, Kleber TJ, Switchenko JM, Kaufman JL, et al. Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA. Lancet Haematol 2024; 11: e510-e520.
Zhang SC, Kim S, Steers J, Stiehl B, Silos KD, Grigsby G, et al. Irradiated bone marrow volume is associated with hematologic toxicity in patients with multiple myeloma. Int J Radiat Oncol Biol Phys 2025; 121: 1026-1038.
Oertel M, Schlusemann T, Shumilov E, Reinartz G, Bremer A, Rehn S, et al. Radiotherapy in combination with systemic therapy for multiple myeloma-a critical toxicity evaluation in the modern treatment era. Cancers (Basel) 2023; 15: 2909.
Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S, et al. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies. Blood 2024; 144: 2375-2388..
Nieder C, Jensen SM, Nilsen S, Haukland EC. Palliative radiation treatment in patients managed with advanced/interventional pain therapy such as pump-delivered continuous opioids. Anticancer Res 2024; 44: 4419-4425.
Lang K, König L, Bruckner T, Förster R, Sprave T, Schlampp I, et al. Stability of spinal bone lesions in patients with multiple myeloma after radiotherapy – a retrospective analysis of 130 cases. Clin Lymphoma Myeloma Leuk 2017; 17: e99-e107.
Stölting T, Knauerhase H, Klautke G, Kundt G, Fietkau R. Total and single doses influence the effectiveness of radiotherapy in palliative treatment of plasmacytoma. Strahlenther Onkol 2008; 184: 465-472.
Sharma AM, Sackett M, Bueddefeld D, Lambert P, Dubey A, Wadhwa V, et al. Incidence of spinal disease and role of spinal radiotherapy in multiple myeloma. Curr Oncol 2018; 25: e539-e544.
Dimopoulos MA, Terpos E, Boccadoro M, Moreau P, Mateos MV, Zweegman S, et al. EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol 2025; 22: 680-700.
Willmann J, Appelt AL, Balermpas P, Baumert BG, de Ruysscher D, Hoyer M, et al. Re-irradiation in clinical practice: Results of an international patterns of care survey within the framework of the ESTRO-EORTC E2-RADIatE platform. Radiother Oncol 2023; 189: 109947.
Nieder C, Willmann J, Andratschke NH. Prospective randomized clinical studies involving reirradiation: update of a systematic review. Strahlenther Onkol 2023; 199: 787-797.
Van Aken ESM, Devnani B, Castelo-Branco L, de Ruysscher D, Martins-Branco D, Marijnen CAM, et al. ESMO-ESTRO framework for assessing the interactions and safety of combining radiotherapy with targeted cancer therapies or immunotherapy. Radiother Oncol 2025; 208: 110910.
